Lyell Immunopharma (LYEL) EBT Margin: 2020-2025
Historic EBT Margin for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to -226,580.00%.
- Lyell Immunopharma's EBT Margin fell 9558000.00% to -226,580.00% in Q3 2025 from the same period last year, while for Sep 2025 it was -798,982.93%, marking a year-over-year decrease of 49599245.00%. This contributed to the annual value of -548,667.21% for FY2024, which is 37670183.00% down from last year.
- According to the latest figures from Q3 2025, Lyell Immunopharma's EBT Margin is -226,580.00%, which was up 58.68% from -548,300.00% recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's EBT Margin registered a high of -23.42% during Q4 2022, and its lowest value of -2,139,533.33% during Q3 2022.
- Over the past 3 years, Lyell Immunopharma's median EBT Margin value was -347,415.38% (recorded in 2024), while the average stood at -577,603.43%.
- In the last 5 years, Lyell Immunopharma's EBT Margin slumped by 213,775,871bps in 2022 and then spiked by 192,980,933bps in 2023.
- Over the past 5 years, Lyell Immunopharma's EBT Margin (Quarterly) stood at -1,673.10% in 2021, then surged by 164,969bps to -23.42% in 2022, then plummeted by 40,323,812bps to -403,261.54% in 2023, then slumped by 138,062,028bps to -1,783,881.82% in 2024, then plummeted by 9,558,000bps to -226,580.00% in 2025.
- Its EBT Margin stands at -226,580.00% for Q3 2025, versus -548,300.00% for Q2 2025 and -764,357.14% for Q1 2025.